Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (> 5 cm...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Wierda, William G., Padmanabhan, Swaminathan, Chan, Geoffrey W., Gupta, Ira V., Lisby, Steen, Österborg, Anders
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2011
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916553/
https://ncbi.nlm.nih.gov/pubmed/21856867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-348656
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items